{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:49:52Z","timestamp":1781063392983,"version":"3.54.1"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die systemische Sklerose (SSc) ist eine Kollagenose multifaktorieller Genese, bei der autoimmune Entz\u00fcndungsreaktionen zur Fibrosierung diverser Gewebe f\u00fchren. In der Vergangenheit war die renale Krise eine h\u00e4ufige Komplikation mit sehr hoher Mortalit\u00e4t. Aufgrund der Empfehlung zum vorsichtigeren Einsatz von Glukokortikoiden und der Nutzung von ACE-Inhibitoren als Akutbehandlung hat sich die Inzidenz und Prognose der renalen Krise allerdings seit den 1980er-Jahren deutlich gebessert. Mittlerweile ist die Lungenbeteiligung, inklusive pulmonaler arterieller Hypertonie, interstitieller Lungenerkrankung und Lungenfibrose, die h\u00e4ufigste Todesursache bei SSc. Eine fr\u00fche Erkennung, auch mittels Screening-HR-CT, und die ad\u00e4quate Behandlung der interstitiellen Lungenerkrankung sind daher von h\u00f6chster Wichtigkeit. Mycophenolat-Mofetil (MMF) hat sich hierf\u00fcr als ein wirkungsvolles Basis-Therapeutikum herausgestellt. Nintedanib ist das einzige in Deutschland zugelassene Medikament zur Therapie der progredienten Lungenfibrose bei SSc. In Studien zeigten sich die besten Prognose-Verbesserungen bei fr\u00fchzeitiger Kombinationstherapie von MMF mit Nintedanib.<\/jats:p>","DOI":"10.1055\/a-2615-9127","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:40:46Z","timestamp":1754433646000},"page":"975-979","source":"Crossref","is-referenced-by-count":1,"title":["Von der renalen Krise zur Lungenfibrose \u2013 die systemische Sklerose im Wandel"],"prefix":"10.1055","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3967-9847","authenticated-orcid":false,"given":"Kai Martin","family":"Jahns","sequence":"additional","affiliation":[{"name":"I Medizinische Klinik Schwerpunkt Rheumatologie und klinische Immunologie, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9171-3780","authenticated-orcid":false,"given":"Matthias","family":"Dreher","sequence":"additional","affiliation":[{"name":"I Medizinische Klinik Schwerpunkt Rheumatologie und klinische Immunologie, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"},{"name":"Universit\u00e4res Centrum f\u00fcr Autoimmunit\u00e4t, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Triantafyllias","sequence":"additional","affiliation":[{"name":"RZ Rheumazentrum Rheinland-Pfalz GmbH, Bad Kreuznach, Deutschland,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Ha\u00dfdenteufel","sequence":"additional","affiliation":[{"name":"I Medizinische Klinik Schwerpunkt Rheumatologie und klinische Immunologie, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[{"name":"I Medizinische Klinik Schwerpunkt Rheumatologie und klinische Immunologie, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"},{"name":"Universit\u00e4res Centrum f\u00fcr Autoimmunit\u00e4t, Universit\u00e4tsmedizin Mainz, Mainz, Deutschland"},{"name":"RZ Rheumazentrum Rheinland-Pfalz GmbH, Bad Kreuznach, Deutschland,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers","volume":"64","author":"I Cavazzana","year":"2022","journal-title":"Clinic Rev Allerg Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis","volume":"60","author":"M Bairkdar","year":"2021","journal-title":"Rheumatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry","volume":"117","author":"P Gourh","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1093\/rheumatology\/keaa127","article-title":"Older age onset of systemic sclerosis \u2013 accelerated disease progression in all disease subsets","volume":"59","author":"P Moinzadeh","year":"2020","journal-title":"Rheumatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/rheumatology\/key151","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","volume":"58","author":"D Khanna","year":"2019","journal-title":"Rheumatology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MD.0000000000000018","article-title":"Early- versus Late-Onset Systemic Sclerosis: Differences in Clinical Presentation and Outcome in 1037 Patients","volume":"93","author":"MA Alba","year":"2014","journal-title":"Medicine"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40674-016-0050-y","article-title":"Autoantibodies and Their Role in Scleroderma Clinical Care","volume":"2","author":"RT Domsic","year":"2016","journal-title":"Curr Treat Options in Rheum"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.autrev.2018.03.012","article-title":"Therapy of scleroderma renal crisis: State of the art","volume":"17","author":"E Zanatta","year":"2018","journal-title":"Autoimmunity Reviews"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"VD Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"AJ Tyndall","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: Systematic review and meta-analysis","volume":"44","author":"M Rubio-Rivas","year":"2014","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"10","key":"ref12","first-page":"831","article-title":"Red flags in scleroderma","volume":"37","author":"Q Li","year":"2008","journal-title":"Australian Family Physician"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.732761","article-title":"Interstitial Lung Disease Associated With Autoimmune Rheumatic Diseases: Checklists for Clinical Practice","volume":"8","author":"SL Bosello","year":"2021","journal-title":"Front Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11926-022-01067-5","article-title":"Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis","volume":"24","author":"SA Khanna","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/a-1658-5176","article-title":"Moderne medikament\u00f6se Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose","volume":"147","author":"M Aringer","year":"2022","journal-title":"Dtsch Med Wochenschr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25469","article-title":"Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database","author":"D Mongin","year":"2025","journal-title":"Arthritis Care & Research"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","author":"FD Galdo","year":"2024","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref18","first-page":"S87","article-title":"Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement","volume":"22","author":"K Takehara","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-018-1517-z","article-title":"Systemic sclerosis associated interstitial lung disease \u2013 individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group","volume":"20","author":"S Adler","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"DP Tashkin","year":"2016","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"O Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"S Ebata","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"D Khanna","year":"2016","journal-title":"The Lancet"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"D Khanna","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002477","article-title":"Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","volume":"8","author":"S Kuster","year":"2022","journal-title":"RMD Open"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"J Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"KB Highland","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","article-title":"The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements","volume":"2","author":"A-M Hoffmann-Vold","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"FF Rahaghi","year":"2023","journal-title":"Respir Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of Systemic Sclerosis\u2013associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"G Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2615-9127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T22:40:58Z","timestamp":1754433658000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2615-9127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2615-9127","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}